Aktualisierung der S3-Leitlinie Colitis ulcerosa 2019

Z Gastroenterol 2019; 57(11): 1279-1280
DOI: 10.1055/a-1015-7048

Editorial

Authors

Torsten Kucharzik

¹Klinikum Lüneburg, Klinik für Allgemeine Innere Medizin und Gastroenterologie, Lüneburg
Axel Dignaß

²Medizinische Klinik 1, Agaplesion Markus Krankenhaus, Frankfurt/Main; Frankfurt am Main
Britta Siegmund

³Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie, Berlin, Germany

Literatur
1 Updated S3-Guideline Colitis ulcerosa. German Society for Digestive and Metabolic Diseases (DGVS) – AWMF Registry 021/009. Z Gastroenterol 2018; 56: 1087-1169
2 Sandborn WJ, Su C, Panes J. Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2017; 377: 496-497
3 Sandborn WJ, Panes J, DʼHaens GR. et al. Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. Clin Gastroenterol Hepatol 2019; 17: 1541-1550
4 Moussata D, Allez M, Cazals-Hatem D. et al. Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy?. Gut 2018; 67: 616-624
5 McDonald LC, Gerding DN, Johnson S. et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66: 987-994
6 Beinortas T, Burr NE, Wilcox MH. et al. Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis. Lancet Infect Dis 2018; 18: 1035-1044
7 Horton HA, Dezfoli S, Berel D. et al. Antibiotics for Treatment of Clostridium difficile Infection in Hospitalized Patients with Inflammatory Bowel Disease. Antimicrob Agents Chemother 2014; 58: 5054-5059